Guardant Health, Inc. GH

Guardant Health earned a spot on Investor's Business Daily Leaderboard. The FDA approved Guardant360 CDx as a companion diagnostic for AstraZeneca's Etcamah in advanced or metastatic breast cancer, the first FDA-approved liquid biopsy CDx for longitudinal testing in breast cancer. The milestone broadens Guardant's potential revenue tied to targeted therapies and strengthens the role of liquid biopsy in ongoing disease monitoring. FDA approval expands Guardant's addressable market in breast cancer and validates its liquid biopsy platform.

Guardant Health secures first FDA clearance for liquid biopsy test in breast cancer, enabling non-invasive detection and monitoring. First FDA clearance for breast cancer liquid biopsy strengthens Guardant Health's regulatory edge and commercial opportunities in oncology diagnostics.

Guardant Health nears a buy point as its sales outlook brightens. Brightening sales outlook supports better financial results and lifts investor sentiment for Guardant Health.

Guardant Health may gain from AstraZeneca trial failure according to UBS. AstraZeneca trial failure may lift Guardant Health positioning in cancer diagnostics per analyst view.

Guardant Health’s Shield blood test gains coverage from EviCore by Evernorth for colorectal cancer screening. EviCore coverage expands Shield test access and supports higher adoption for Guardant Health.

Guardant Health and collaborators will present 20 abstracts on liquid biopsy tests for early detection and ongoing treatment management of lung cancer at the 2026 World Conference on Lung Cancer. Presentations of 20 abstracts at a major lung cancer conference increase visibility for Guardant Health's liquid biopsy portfolio among specialists.

Guardant Health advances liquid biopsy tests for cancer detection with rising adoption, new partnerships and expanding oncology market opportunities that support revenue growth and competitive positioning. Strategic progress in liquid biopsy and market expansion are positioned to materially lift future revenue and investor sentiment.

Guardant Health is positioned as the one growth stock worth adding to investor portfolios while two other companies are recommended for avoidance based on their weaker prospects. Stock recommendation directly influences investor sentiment and short-term trading activity for Guardant Health.

Guardant Health gains FDA approval for Guardant360 CDx as companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. FDA approval expands Guardant360 CDx use in breast cancer and strengthens core oncology diagnostic positioning.

Guardant Health faces a $245 million patent judgment, but its newer tests could offer protection. Large patent judgment creates financial pressure that is offset by protection from newer tests.

Guardant Health secures Carelon Health Services coverage for its Shield blood test in colorectal cancer screening. Carelon coverage expands Shield test access and drives revenue growth for Guardant Health colorectal screening.

A US$245 million patent ruling has potentially altered Guardant Health's investment narrative and market outlook. A $245 million patent ruling constitutes a major legal and financial event likely to shift the company's trajectory.

Guardant Health secured a US$245 million patent ruling that triggered questions over whether its shares have risen excessively in reaction to the award. The $245 million patent victory materially improves Guardant Health's cash position and intellectual property strength.

Guardant Health, Inc. (GH) has been ordered to pay $245 million in a patent dispute. A $245 million payment obligation imposes a major financial burden that can materially affect Guardant Health's cash position and investor sentiment.

Guardant Health was ordered to pay $245 million in a DNA sequencing patent dispute. The $245 million patent payout imposes a major financial hit that will likely constrain Guardant Health's cash flow and alter its near-term trajectory.

TwinStrand Biosciences secures a final judgment in a patent infringement suit against Guardant Health, awarding TwinStrand and the University of Washington more than $245.2 million in damages, accrued royalties, and interest. Guardant Health faces a $245 million patent infringement judgment that imposes major financial liability and competitive constraints.

Guardant Health plans to appeal a Federal District Court judgment. Ongoing legal appeals create uncertainty and potential costs that may moderately affect financial performance.

Guardant Health loses patent dispute with judge ordering royalty payments, triggering stock decline. Royalty payments from lost patent dispute create ongoing financial costs and pressure on performance.

Guardant Health (GH) stock surges after FDA approval boosts momentum in cancer screening. FDA approval marks a pivotal regulatory success likely to accelerate Guardant Health commercial growth in oncology diagnostics.

Guardant Health reports accelerated growth in Shield, MRD and oncology testing volumes, signaling stronger adoption across its core diagnostic offerings. Accelerated uptake of flagship tests expands revenue base and competitive positioning in precision oncology.

Tempus AI secures FDA approval that could unlock major reimbursement growth for its oncology tests, intensifying competition for Guardant Health in liquid biopsy and precision medicine markets. Competitor Tempus AI's FDA win and reimbursement gains may moderately shift market dynamics and investor sentiment for Guardant Health.

Guardant Health (GH) releases information prompting investor reevaluation of the company's prospects. Company update creates moderate market sentiment shift without altering core operations or trajectory.

Guardant Health held its Q2 2026 earnings call to discuss financial results and business updates. Earnings call details financial performance and outlook with potential to influence near-term stock movement.

Guardant Health reports 48% growth fueled by rising adoption of its cancer tests. 48% growth in core cancer testing directly boosts revenue outlook and competitive position.

Guardant Health posts strong Q2 revenue growth fueled by expanded Shield coverage and rising oncology uptake. Shield coverage gains and oncology uptake directly lift revenue and strengthen Guardant Health's market trajectory.

Guardant Health faces ongoing growth stock challenges but is positioned as a hold recommendation in the health care sector due to its operational stability. Title signals moderate investor positioning advice without evidence of major strategic or regulatory shifts.

Guardant Health raises 2026 outlook, triggering a stock spike and selection as Thursday's stock of the day. Raised 2026 outlook directly lifts growth expectations and triggers immediate stock gains.

Guardant Health held its Q2 2026 earnings call, reporting financial results, operational updates, and forward guidance. Q2 2026 earnings call delivers key financial metrics and strategic outlook that typically drive major shifts in investor sentiment and stock trajectory.

Guardant Health Inc reported 44% revenue growth in Q2 2026 driven by FDA approval of its oncology testing products. FDA approval combined with 44% revenue surge indicates major commercial momentum and expanded market access.

Guardant Health Q2 earnings call highlights key financial results and strategic updates. Quarterly earnings details can influence short-term stock sentiment but rarely shift long-term company trajectory alone.